DLBCL Discussions: ASH 2021 – ENG

POLARIX

ASH 2021

Part I: Pola-R-CHP - possible new standard in 1st line?

A. M. Niebla, M. Dreyling, C. Thieblemont, M. Jerkeman,  M. Ladetto, T. Eyre

ZUMA-7, TRANSFORM, Belinda

ASH 2021

Part II: CAR-T cells - all over the field data for…

A. M. Niebla, M. Dreyling, C. Thieblemont, M. Jerkeman,  M. Ladetto, T. Eyre

DLBCL – ENG

ZUMA-7, BELINDA, TRANSFORM

ASH 2021

axi-cel, tisa-cel, liso-cel: New CAR-T options for R/R…

Martin Dreyling, MD

POLARIX

ASH 2021

pola-R-CHP vs. R-CHOP: a new standard?

Martin Dreyling, MD

ZUMA‑7

ASH 2021

Axi-cel - new standard for r/r LBCL patients?

Marco Ladetto, MD

ASH 2021

Prevention of CNS relapse after R-CHOP

Marco Ladetto, MD

ASH 2021

HD-MTX does not lower SCNS rates in high-risk patients

Mats Jerkeman, MD

BELINDA

ASH 2021

Tisa-cel - new CAR-T option for R/R aNHL

Mats Jerkeman, MD

DLBCL – GER/ITA

ZUMA‑7

ASH 2021

Axi Cel: un nuovo standard nel DLBCL recidivato o…

Marco Ladetto, MD

ASH 2021

La prevenzione della recidiva a carico del sistema…

Marco Ladetto, MD

POLARIX

ASH 2021

pola-R-CHP vs. R-CHOP: Neuer Standard?

Martin Dreyling, MD

ZUMA-7, BELINDA, TRANSFORM

ASH 2021

Axi-Cel I Tisa-Cel I Liso-Cel: Drei neue CAR-T-Optionen…

Martin Dreyling, MD

Mantle Cell Lymphoma Discussions: ASH 2021 – ENG

MCL R2 Elderly

ASH 2021

Part I: Potential change in first-line treatment?

A. M. Niebla, M. Dreyling, C. Thieblemont, M. Jerkeman,  M. Ladetto, T. Eyre

BRUIN

ASH 2021

Part II: The white elephant in the room - BTKi

A. M. Niebla, M. Dreyling, C. Thieblemont, M. Jerkeman,  M. Ladetto, T. Eyre

Mantle Cell Lymphoma – ENG

ASH 2021

Encouraging real world safety and efficacy data of…

Ana Marín Niebla, MD, PhD

BRUIN

ASH 2021

Next generation BTKI Pirtobrutinib

Martin Dreyling, MD

ASH 2021

Glofitamab SUD as monotherapy after Gpt induced high…

Mats Jerkeman, MD

MCL Younger

ASH 2021

HiDAC-containing induction before ASCT substantially…

Ana Marín Niebla, MD PhD

MCL R2 Elderly

ASH 2021

Low-dose lenalidomide added to rituximab maintenance in…

Ana Marín Niebla, MD, PhD

BRUIN, BRUIN MCL-321

ASH 2021

Pirtobrutinib shows promising efficacy and safety in…

Ana Marín Niebla, MD PhD

MCL R2 Elderly

ASH 2021

Focus on maintenance is critical in MCL

Marco Ladetto, MD

MCL R2 Elderly

ASH 2021

Maintenance with Rituximab-Lenalidomid (R2)

Martin Dreyling, MD

BRUIN

ASH 2021

Pirtobrutinib - promising agent moving forward

Toby A. Eyre, MD

Mantle Cell Lymphoma – GER/ITA/ESP

ASH 2021

Eficacia y seguridad de brexu-cel en pacientes con LCM…

Ana Marín Niebla, MD PhD

MCL R2 Elderly

ASH 2021

Añadir lenalidomida a dosis bajas a rituximab en el…

Ana Marín Niebla, MD PhD

MCL R2 Elderly

ASH 2021

Rituximab-Lenalidomid Erhaltungstherapie (R2)

Martin Dreyling, MD

BRUIN, BRUIN MCL-321

ASH 2021

Pirtobrutinib es eficaz y seguro en pacientes muy…

Ana Marín Niebla, MD PhD

BRUIN

ASH 2021

Pirtobrutinib: Neuer, nicht-kovalenter BTKi

Martin Dreyling, MD

MCL Younger

ASH 2021

La inducción con citarabina a dosis altas antes del…

Ana Marín Niebla, MD PhD

MCL R2 Elderly

ASH 2021

Ruolo del mantenimento con R2 nel linfoma mantellare

Marco Ladetto, MD

Follicular Lymphoma Discussions: ASH 2021 – ENG

ZUMA-5, ELARA

ASH 2021

Part I: CAR-T cells on the way

A. M. Niebla, M. Dreyling, C. Thieblemont, M. Jerkeman,  M. Ladetto, T. Eyre

ASH 2021

Part II: Bi-specific antibodies as an attractive agent

A. M. Niebla, M. Dreyling, C. Thieblemont, M. Jerkeman,  M. Ladetto, T. Eyre

Follicular Lymphoma – ENG

ASH 2021

Novel immunotherapy approaches to R/R follicular…

Martin Dreyling, MD

FOLL12

ASH 2021

MRD monitoring in follicular lymphoma is extremely…

Marco Ladetto, MD

FOLL12

ASH 2021

First-line options and RM

Martin Dreyling, MD

ASH 2021

Active new therapy for 3L+ R/R FL

Toby A. Eyre, MD

Follicular Lymphoma – GER/ITA

FOLL12

ASH 2021

Rituximab-Erhaltung nach ICT bleibt Standard

Martin Dreyling, MD

ASH 2021

Mosunetuzumab + Lenalidomid beim r/r FL

Martin Dreyling, MD

FOLL12

ASH 2021

Ruolo del monitoraggio della malattia minima residua…

Marco Ladetto, MD

Chronic/Small Lymphocytic Leukemia Discussions: ASH 2021 – ENG

BRUIN CLL, SEQUOIA

ASH 2021

Part I: Promising data in CLL

A. M. Niebla, M. Dreyling, C. Thieblemont, M. Jerkeman,  M. Ladetto, T. Eyre

CLL13 / GAIA, FLAIR

ASH 2021

Part II: More data to wait for

A. M. Niebla, M. Dreyling, C. Thieblemont, M. Ladetto, T. Eyre

Chronic/Small Lymphocytic Leukemia – ENG

BRUIN

ASH 2021

Pirtobrutinib - promising efficacy in heavily…

Toby A. Eyre, MD

SEQUOIA

ASH 2021

BTKi as new option for untreated CLL/SLL patients

Toby A. Eyre, MD

Multiple Myeloma Discussions - ENG

iStopMM

ASH 2021

Big data on smoldering multiple myeloma: the iStopMM…

F. H. Schjesvold, M. Merz, C. O. Landgren, H. Einsele, P. Sonneveld, B. C. Lipe

CASSIOPEIA, Griffin, GMMG-HD7, HOVON 143, etc.

ASH 2021

NDMM: On the way to cure?

F. H. Schjesvold, M. Merz, C. O. Landgren, H. Einsele, P. Sonneveld, B. C. Lipe

MajesTEC-1, TRIMM-2, Magnetismm-1, MonumenTAL-1

ASH 2021

The immunotherapy tsunami continues - bispecific…

H. Einsele, P. Sonneveld, B. C. Lipe, F. H. Schjesvold, M. Merz

CARTITUDE-1, CARTITUDE-2

ASH 2021

The immunotherapy tsunami continues - CAR-T cells

H. Einsele, P. Sonneveld, B. C. Lipe, F. H. Schjesvold, M. Merz

Newly Diagnosed Multiple Myeloma – ENG

Griffin; CASSIOPEIA; MANHATTAN

ASH 2021

The future is already here - the use of antibodies in…

C. Ola Landgren, MD PhD

Griffin

ASH 2021

PFS separation in the Griffin trial

Fredrik Hellem Schjesvold, MD PhD

HOVON 143

ASH 2021

Triplet therapie in elderly patients

Pieter Sonneveld, MD

GMMG-HD7

ASH 2021

Quadruple regimens for NDMM

Pieter Sonneveld, MD

Muknine

ASH 2021

Positive results for high-risk myeloma from the UK

Maximilian Merz, MD

CASSIOPEIA, Griffin

ASH 2021

Quadruple therapy - the treatment of choice in NDMM

Hermann Einsele, MD

GMMG-HD6 Trial

ASH 2021

No benefit for elotuzumab in NDMM

Maximilian Merz, MD

Newly Diagnosed Multiple Myeloma – GER/NOR/SWE

Griffin, CASSIOPEIA, MANHATTAN

ASH 2021

The future is already here - the use of antibodies in…

C. Ola Landgren, MD, PhD

CASSIOPEIA, Griffin

ASH 2021

Quadrupletts Dara-VTd bzw. Dara-RCd erste Optionen bei…

Hermann Einsele, MD

Griffin

ASH 2021

PFS separation in the Griffin trial

Fredrik Hellem Schjesvold, MD PhD

GMMG-HD6 Trial, GMMG-HD7 Trial

ASH 2021

Isatuximab + RVd erfogreich, Elotuzumab nicht

Maximilian Merz, MD

Relapsed/Refractory Multiple Myeloma – ENG

MajesTEC-1; Magnetismm-1; CARTITUDE-1

ASH 2021

New bispecific antibodies and CAR-T cells for RRMM…

C. Ola Landgren, MD PhD

MonumenTAL-1, TRIMM-2

ASH 2021

talquetamab & cevostamab: bispecific antibodies beyond…

Hermann Einsele, MD

BELLINI

ASH 2021

Personalized medicine with venetoclax

Brea C. Lipe, MD

CONPET

ASH 2021

KRd consolidation reverses PET positivity in 1/3 of the…

Fredrik Hellem Schjesvold, MD PhD

Magnetismm-1

ASH 2021

Elranatamab - a new bispecific antibody in RRMM

Maximilian Merz, MD

ASH 2021

TAK-573 - a really new mechanism of treatment in…

Fredrik Hellem Schjesvold, MD PhD

CARTITUDE-1

ASH 2021

Is CAR-T cell treatment better in heavly pretreated…

Pieter Sonneveld, MD

CARTITUDE-1

ASH 2021

cilta-cel: early, deep and durable responses in heavily…

Hermann Einsele, MD

MonumenTAL-1

ASH 2021

Not another BCMA drug

Brea C. Lipe, MD

MajesTEC-1

ASH 2021

Update on bispecific antibody teclistamab

Katja Weisel, MD

CARTITUDE-1

ASH 2021

cilta-cel highly effective in heavily pretreated…

Katja Weisel, MD

Relapsed/Refractory Multiple Myeloma – GER/NOR/SWE

CARTITUDE-1

ASH 2021

cilta-cel hoch erfolgreich bei stark vorbehandelten…

Katja Weisel, MD

CARTITUDE-1

ASH 2021

cilta-cel: frühes, tiefes, lang anhaltendes Ansprechen…

Hermann Einsele, MD

MonumenTAL-1, Magnetismm-3

ASH 2021

CAR-T oder bispezifische MoAk in der Rezidivtherapie -…

Maximilian Merz, MD

MajesTEC-1

ASH 2021

Bispezifischer Antikörper Teclistamab beim r/r MM

Katja Weisel, MD

CONPET

ASH 2021

KRd consolidation reverses PET-positivity in 1/3 of the…

Fredrik Hellem Schjesvold, MD PhD

MonumenTAL-1, TRIMM-2

ASH 2021

Talquetamab und Cevostamab: Neue bispezifische Ak…

Hermann Einsele, MD

MajesTEC-1, Magnetismm-1, CARTITUDE-1

ASH 2021

New bispecific antibodies and CAR-T cells for RRMM…

C. Ola Landgren, MD, PhD

ASH 2021

TAK-573 - a really new mechanism of treatment in…

Fredrik Hellem Schjesvold, MD PhD

Smoldering Myeloma / MGUS – ENG

iStopMM

ASH 2021

MGUS and COVID-19 risk

Brea C. Lipe, MD

iStopMM

ASH 2021

New reference values for light chains in multiple…

Fredrik Hellem Schjesvold, MD PhD

iStopMM

ASH 2021

Myeloma precursor disease 2021

C. Ola Landgren, MD PhD

Smoldering Myeloma / MGUS – NOR/SWE/GER

iStopMM

ASH 2021

New reference values for light chains in multiple…

Fredrik Hellem Schjesvold, MD PhD

iStopMM, PROMISE

ASH 2021

Prävalenz und Risikostratifikation beim SMM

Maximilian Merz, MD

iStopMM

ASH 2021

Myeloma precurser disease 2021

C. Ola Landgren, MD, PhD